Can an HIV drug help beat lung cancer? new trial aims to stop resistance
NCT ID NCT04696575
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding lamivudine, an antiviral drug, to standard chemotherapy and immunotherapy can prevent or delay drug resistance in people with extensive-stage small cell lung cancer. About 28 adults will receive the combination treatment. The goal is to see if this approach improves how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo tested for tough lung cancer – modest hopes
- Brain radiation may be skipped in lung cancer: new trial tests safer monitoring
- New antibody drug targets tough lung cancer in early trial
- New program aims to boost strength and mood in older lung cancer patients
- Triple-Drug cocktail aims to keep lung cancer at bay
- New combo aims to boost chemo for tough lung cancer